ABIVAX Signs Agreement with the Finlay Institute to Commercialise Meningococcal and Typhoid Vaccines in Asia and Latin America

November 12, 2014 ABIVAX, a leading European, clinical stage biopharmaceutical company developing and commercializing anti-viral compounds and human vaccines, today announced that it has signed an agreement with The Finlay Institute, Havana, Cuba, that will allow it to commercialise vaccines against typhoid, meningococcus, and leptospirosis, in Asian and Latin American markets. Under the terms of the agreement, ABIVAX will gain exclusive …